Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: New findings from an unlinked anonymous monitoring survey

Epidemiology and Infection

Volumn 143, Issue 7, 2015, Pages 1398-1407

  Cullen, K J ^a   Hope, V D ^a,b   Croxford, S ^a   Shute, J ^a   Ncube, F ^a   Parry, J V ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Hepatitis C; people who inject drugs (PWID); recent infection

Indexed keywords

HEPATITIS C ANTIBODY; HEPATITIS C VACCINE;

ADULT; ANTIBODY DETECTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRIED BLOOD SPOT TESTING; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; UNITED KINGDOM; ALGORITHM; HEPACIVIRUS; MIDDLE AGED; PHYSIOLOGY; RISK; SUBSTANCE ABUSE; VIROLOGY; YOUNG ADULT;

ADULT; ALGORITHMS; ENGLAND; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORTHERN IRELAND; ODDS RATIO; QUESTIONNAIRES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; WALES; YOUNG ADULT;

EID: 84926419311     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268814002040     Document Type: Review

References (41)

1. World Health Organization. Global alert and response. Hepatitis C. (http://www.who.int/csr/disease/hepatitis/Hepc.pdf). Accessed 28 August 2013
2. Craine N, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection 2009; 137: 1255-1265.
3. Miller CL, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-742.
4. Health Protection Agency. Shooting up: infections among people who inject drugs in the United Kingdom 2011. London: Health Protection Agency Centre for Infections, 2012.
5. Public Health England Centre for Infections. Hepatitis C in the UK. London: Public Health England, 2013.
6. NHS Choices. Hepatitis C: quick reference guide for primary care. (http://www.nhs.uk/hepatitisc/SiteCollection Documents/pdf/Hepatitis-C-quick-reference-for-PC-April2011.pdf). Accessed 29 July 2013.
7. Van Den Berg C, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462.
8. Smyth BP, et al. Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin. Journal of Epidemiology and Community Health 2003; 57: 310-311.
9. Aarons E, et al. Failure to diagnose recent hepatitis C virus infections in London injecting drug users. Journal of Medical Virology 2004; 73: 548-553.
10. Balogun MA, et al. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiology and Infection 2009; 137: 980-987.
11. Judd A, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal 2005; 330: 24-25.
12. Turner KM, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978-1988.
13. Brant LJ, et al. Diagnosis of acute hepatitis C virus infection and estimated incidence in low-and high-risk English populations. Journal of Viral Hepatatis 2008; 15: 871-877.
14. Abou-Saleh M, et al. The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduction Journal 2008; 5: 25.
15. Roy KM, et al. Amethod to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993-98. Journal of Infection 2001; 43: 200-205.
16. Chawla A, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. Journal of Clinical Microbiology 2007; 45: 415-420.
17. Gaudy-Graffin C, et al. Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection. JournalofClinicalMicrobiology2010; 48: 3281-3287.
18. Shepherd SJ, et al.Ahepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. Journal of Clinical Virology 2013; 57: 29-35.
19. Klimashevskaya S, et al. Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index. Journal of Clinical Microbiology 2007; 45: 3400-3403.
20. Noone A, et al. HIV infection in injecting drug users attending centres in England and Wales, 1990-1991. AIDS 1993; 7: 1501-1507.
21. Hope VD, et al. HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS 2005; 19: 1207-1214.
22. Connell JA, et al. Novel assay for the detection of immunoglobulin G antihuman immunodeficiency virus in untreated saliva and urine. Journal of Medical Virology 1993; 41: 159-164.
23. Judd A, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology 2003; 71: 49-55.
24. Mellor J, et al. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. Journal of General Virology 1995; 76: 2493-2507.
25. Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Eurosurveillance 2008; 13.
26. Maher L, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006; 101: 1499-1508.
27. Maher L, et al. High hepatitis C incidence in new injecting drug users: a policy failure? Australian and New Zealand Journal of Public Health 2007; 31: 30-35.
28. De IJ, et al. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. American Journal of Epidemiology 1996; 143: 725-732.
29. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993; 88: 517-526.
30. The Hepatitis C Trust. Stages of hepatitis C (http://www. hepctrust.org.uk/Hepatitis-C-Info/Stages+of+Hepatitis+ C/The+acute+phase). Accessed 29 October 2013.
31. Iversen J, et al. Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. International Journal of Drug Policy 2010; 21: 471-476.
32. Maher L, et al. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in southwestern Sydney, Australia. Journal of Gastroenterology and Hepatology 2004; 19: 1114-1120.
33. Hope VD, et al. Prevalence of hepatitis C among injection drug users in England andWales: is harm reduction working? Americal Journal of Public Health 2001; 91: 38-42.
34. Macalino GE, et al. Hepatitis C infection and incarcerated populations. International Journal of Drug Policy 2003; 15: 103-114.
35. Pontali E, Ferrari F. Prevalence of hepatitis B virus and/or hepatitis C virus co-infections in prisoners infected with the Human immunodeficiency virus. International Journal of Prisoner Health 2008; 4: 77-82.
36. Weild AR, et al. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Communicable Disease and Public Health 2000; 3: 121-126.
37. van Beek I, et al. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. British Medical Journal 1998; 317: 433-437.
38. Patrick DM, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal 2001; 165: 889-895.
39. Merrall EL, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction 2010; 105: 1545-1554.
40. Pinkham S, Stoicescu C, Myers B. Developing effective health interventions for women who inject drugs: key areas and recommendations for program development and policy. Advanced Preventative Medicine 2012; 2012.
41. Kapadia F, et al. Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? Epidemiology 2002; 13: 738-741.